390 million treatments of Coartem® Dispersible (artemether-lumefantrine), the first paediatric dispersible ACT developed especially for children with malaria, delivered to more than 50 malaria-endemic countries since launch in 2009
- 86% of malaria deaths are in children under the age of 5 and they urgently require medicines tailored for their needs
- Coartem Dispersible is the product of the partnership between MMV and Novartis, supporting the UNICEF/WHO backed the call to develop child-friendly medicines
- Coartem Dispersible is a sweet-tasting cherry-flavoured tablet that disperses in a small amount of water and is especially developed for and well accepted by children. It is the first and only prequalified child-friendly ACT
- Measures have been taken to facilitate the uptake of this medicine: from registration in 40 countries to not-for-profit pricing and packaging designed to improve compliance
- There has been a rapid acceptance and uptake of Coartem Dispersible underlining the advantage of the paediatric formulation
Need for Paediatric Treatment
Young children in Africa are disproportionately affected by malaria, with the vast majority of malaria deaths occurring in children1.
- Over 650,000 people die of malaria around the world.
- Nine out of ten malaria-related deaths occur in sub-Saharan Africa and 86% of those occur in children under the age of 5.
- In Africa alone, a child dies every 60 seconds from malaria.
Coartem Dispersible is the first and only high quality, fixed-dose artemisinin-based dispersible combination therapy (ACT) tablet tailored for children.
- Coartem Dispersible was developed to address the specific treatment needs of children with malaria.
- The new, sweet-tasting Coartem Dispersible tablets disperse quickly in small amounts of water, easing administration and ensuring effective and accurate dosing for children.
Coartem Dispersible has been provided to the public sector without profit to benefit those people most in need in malaria-endemic countries.
- Coartem Dispersible addresses an unmet medical need - underscoring Novartis and MMV’s commitment to reaching the MDG of reducing childhood mortality.
Coartem Dispersible pricing
- The cost of a Coartem Dispersible treatment course is the same as Coartem®, with treatment for the youngest patients at USD 0.38.
- Since 2001, Novartis has supplied more than 390 million Coartem treatments to the public sector without profit and this arrangement continues with Coartem Dispersible.
Coartem Dispersible’s packaging is designed to improve patient compliance.
- Instructions on the Coartem Dispersible packaging are described pictorially as well as in-text so as to make it appropriate, easy to understand, and effective.
Value of Partnership and Collaboration
Development and delivery of Coartem Dispersible was made possible thanks to the partnership between MMV and Novartis.
- Responding to the international community’s call for the development of paediatric formulations of medicines, Novartis and MMV signed a partnership agreement in 2003 to develop the first ACT especially for children with malaria.
- The result was Coartem Dispersible, a sweet-tasting and quick-dispersing formulation to ease administration for young children and to ensure effective dosing for malaria’s youngest victims. The drug was launched in 2009.
- The development of Coartem Dispersible has proved that drug development partnerships can not only succeed but can truly advance the fight against malaria.
- The development of this new paediatric formulation was made possible thanks to investment from the public, philanthropic, and private sectors.
MMV’s Commitment to Malaria Research
The success of this innovative medicine provides momentum to MMV’s commitment to continue its important work in the hunt for new antimalarials to address unmet needs.
- We are working to develop new medicines to counter resistance, stop transmission, and provide a radical cure for P. vivax malaria.
- Our ultimate goal is a one-dose cure that will help eradicate this deadly disease.
1. World Malaria Report, Geneva: World Health Organization.